Stevanato Group as unveiled its latest release of its patented on-body drug delivery system, Vertiva. The device is designed with the ability to switch between basal and bolus injections and is suitable for a wide range of subcutaneous therapies1.
Vertiva’s unique design consists of a single-use pod with a pre-filled and pre-loaded 3mL ISO cartridge, and a multi-use controller, offering potential sustainability and affordability benefits. The device can adapt to different delivery profiles and can enable the administration of small-molecule drugs and biologics.
“The Vertiva on-body delivery system supports pharma companies in increasing the accessibility of in-home care and administered treatment options, which can ultimately lead to an improved patient experience,” said Steven Kaufman, VP for drug delivery systems at Stevanato Group.
Sign up to the free weekly newsletter for all the latest news, resources and podcasts in contract manufacturing. 
LIVE in Rotterdam, 7-8 May 205 
